Does Valproic Acid Deplete Vitamin K? What the Research Says

Yes, valproic acid can deplete vitamin K and interfere with vitamin K-dependent coagulation processes. This interaction is clinically significant in two contexts: chronic use affecting bleeding risk, and pregnancy where neonatal hemorrhagic disease becomes a concern. Valproic acid affects the hepatic synthesis of vitamin K-dependent clotting factors (Factors II, VII, IX, and X) and may reduce vitamin K recycling through effects on the vitamin K epoxide reductase pathway. Optimal vitamin K levels fall between 0.5-2.5 ng/mL, though standard testing focuses more on functional coagulation markers (PT/INR) than direct vitamin K levels. Patients on valproic acid who report easy bruising, prolonged bleeding from cuts, or nosebleeds should have their coagulation status evaluated.

The vitamin K evidence base includes 139 RCTs across 885,186 patients tracked in CTD, with 194 meta-analyses documented in PubMed. Valproic acid's 3,337 indexed articles include specific investigations of its effects on coagulation. FAERS adverse event reports for valproic acid include thrombocytopenia, bruising, and bleeding events, though thrombocytopenia (low platelet count) is more commonly reported than vitamin K-specific effects. Case reports document neonatal hemorrhagic disease in infants born to mothers taking valproic acid, with vitamin K depletion identified as a contributing factor alongside direct platelet effects. Coagulation studies in chronic valproic acid users occasionally demonstrate prolonged PT/INR or reduced levels of specific vitamin K-dependent factors, though these findings are less consistent than the thrombocytopenic effects. The 4,545 PubMed articles indexing vitamin K provide context for understanding its essential role in both coagulation and bone metabolism.

Valproic acid affects vitamin K metabolism through several pathways. First, valproic acid undergoes extensive hepatic metabolism that may compete with vitamin K-dependent carboxylation of clotting factors, reducing the production of functional Factors II, VII, IX, and X. Second, valproic acid's HDAC inhibition may alter the expression of genes involved in vitamin K recycling, specifically the vitamin K epoxide reductase complex (VKORC1), reducing the efficiency of vitamin K regeneration. Third, valproic acid can directly suppress platelet production through bone marrow effects, creating a compounded bleeding risk that combines vitamin K-related clotting factor deficiency with reduced platelet numbers. The vitamin K effects are generally milder than valproic acid's more prominent platelet effects, but the combination creates additive bleeding risk, particularly during surgical procedures or trauma.

If you take valproic acid, your healthcare provider should periodically check coagulation markers including PT/INR and a complete blood count with platelet count. Report any unusual bruising, prolonged bleeding from minor cuts, nosebleeds, or heavy menstrual periods. Pregnant women on valproic acid should receive vitamin K supplementation (10 mg daily) during the last month of pregnancy, and their newborns should receive vitamin K at birth to prevent neonatal hemorrhagic disease. For non-pregnant patients, dietary vitamin K intake from leafy greens (kale, spinach, broccoli, Brussels sprouts) should be maintained at a consistent, adequate level. Supplemental vitamin K (100-150 mcg daily as K1 or K2) may be appropriate for chronic valproic acid users with documented coagulation abnormalities. Always inform surgeons and dentists about your valproic acid use before any procedure, as additional bleeding precautions may be warranted.